Development of Secondary Cancers in Pre- vs Post-ICI Eligibility Periods for Metastatic Cancers
Athena Li, Jiyeong Kim, Thet Su Win, Michael L. Chen
TL;DR
This study compares the occurrence of secondary cancers in patients with metastatic cancer before and after the availability of immune checkpoint inhibitors.
Contribution
The study provides new insights into how the use of immune checkpoint inhibitors may influence the development of secondary cancers.
Findings
The incidence of secondary cancers was analyzed in relation to ICI approval timelines.
Findings suggest a potential association between ICI use and secondary cancer development.
The study highlights the importance of long-term monitoring of cancer patients treated with ICIs.
Abstract
This cohort study investigates incidence of secondary primary cancers before vs after approval of immune checkpoint inhibitors (ICIs) among patients with metastatic cancers.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMultiple and Secondary Primary Cancers · Cancer Immunotherapy and Biomarkers · Cancer Diagnosis and Treatment